InMode (INMD) Competitors $13.74 +0.08 (+0.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.85 +0.11 (+0.80%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMD vs. TMDX, NVST, PRCT, WRBY, LIVN, EYE, LMAT, LQDA, ENOV, and CNMDShould you be buying InMode stock or one of its competitors? The main competitors of InMode include TransMedics Group (TMDX), Envista (NVST), PROCEPT BioRobotics (PRCT), Warby Parker (WRBY), LivaNova (LIVN), National Vision (EYE), LeMaitre Vascular (LMAT), Liquidia Technologies (LQDA), Enovis (ENOV), and CONMED (CNMD). These companies are all part of the "medical equipment" industry. InMode vs. Its Competitors TransMedics Group Envista PROCEPT BioRobotics Warby Parker LivaNova National Vision LeMaitre Vascular Liquidia Technologies Enovis CONMED TransMedics Group (NASDAQ:TMDX) and InMode (NASDAQ:INMD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Which has more risk and volatility, TMDX or INMD? TransMedics Group has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Do analysts rate TMDX or INMD? TransMedics Group currently has a consensus price target of $123.00, indicating a potential upside of 2.03%. InMode has a consensus price target of $18.04, indicating a potential upside of 31.31%. Given InMode's higher probable upside, analysts plainly believe InMode is more favorable than TransMedics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransMedics Group 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78InMode 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Does the media favor TMDX or INMD? In the previous week, TransMedics Group had 9 more articles in the media than InMode. MarketBeat recorded 26 mentions for TransMedics Group and 17 mentions for InMode. TransMedics Group's average media sentiment score of 0.78 beat InMode's score of 0.40 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 8 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InMode 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, TMDX or INMD? InMode has lower revenue, but higher earnings than TransMedics Group. InMode is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransMedics Group$441.54M9.31$35.46M$1.9362.46InMode$401.56M2.16$181.27M$2.475.56 Do institutionals & insiders have more ownership in TMDX or INMD? 99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is TMDX or INMD more profitable? InMode has a net margin of 44.50% compared to TransMedics Group's net margin of 13.49%. TransMedics Group's return on equity of 28.02% beat InMode's return on equity.Company Net Margins Return on Equity Return on Assets TransMedics Group13.49% 28.02% 8.64% InMode 44.50%18.38%16.35% SummaryTransMedics Group beats InMode on 12 of the 17 factors compared between the two stocks. Get InMode News Delivered to You Automatically Sign up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMD vs. The Competition Export to ExcelMetricInModeMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$863.44M$10.40B$5.48B$9.53BDividend YieldN/A1.99%4.73%4.09%P/E Ratio5.5618.7328.8923.83Price / Sales2.1629.01371.1466.13Price / Cash7.4922.3135.4557.96Price / Book1.383.478.265.54Net Income$181.27M$234.77M$3.25B$259.28M7 Day Performance-6.66%-4.82%-3.73%-4.67%1 Month Performance-9.66%1.80%4.28%4.37%1 Year Performance-19.93%-12.51%25.85%17.90% InMode Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMDInMode3.1145 of 5 stars$13.74+0.6%$18.04+31.3%-17.1%$863.44M$401.56M5.56480News CoverageEarnings ReportAnalyst ForecastTMDXTransMedics Group2.4639 of 5 stars$105.24-2.7%$129.88+23.4%-20.4%$3.56B$441.54M77.38210Trending NewsEarnings ReportAnalyst ForecastNVSTEnvista3.5834 of 5 stars$20.73-0.3%$20.23-2.4%+22.7%$3.51B$2.51B-3.1712,300Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionPRCTPROCEPT BioRobotics2.5317 of 5 stars$54.08-2.9%$84.13+55.6%-19.4%$2.99B$224.50M-31.81430Upcoming EarningsWRBYWarby Parker2.0734 of 5 stars$24.10-1.2%$22.88-5.1%+48.9%$2.52B$771.32M-200.833,780News CoveragePositive NewsUpcoming EarningsAnalyst ForecastShort Interest ↑Gap DownLIVNLivaNova2.9711 of 5 stars$43.46-0.5%$59.29+36.4%-14.9%$2.37B$1.25B-10.632,900News CoveragePositive NewsUpcoming EarningsEYENational Vision2.8879 of 5 stars$24.48-2.2%$23.00-6.0%+78.3%$1.94B$1.85B-74.1813,411Positive NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionLMATLeMaitre Vascular2.9881 of 5 stars$82.47+0.0%$97.83+18.6%-6.0%$1.86B$219.86M41.65490Upcoming EarningsLQDALiquidia Technologies3.3925 of 5 stars$19.82+1.1%$26.89+35.7%+52.5%$1.69B$14.14M-12.5450News CoverageUpcoming EarningsENOVEnovis2.9571 of 5 stars$27.36-0.7%$55.60+103.2%-44.7%$1.56B$2.11B-1.967,367Upcoming EarningsCNMDCONMED4.4037 of 5 stars$50.05-1.8%$62.20+24.3%-20.0%$1.55B$1.31B13.173,900News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies TMDX Alternatives NVST Alternatives PRCT Alternatives WRBY Alternatives LIVN Alternatives EYE Alternatives LMAT Alternatives LQDA Alternatives ENOV Alternatives CNMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMode Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMode With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
